By Monica Chinyama:
Malawi has committed to ending HIV as a public health threat by 2030 — a goal aligned with global targets set by UNAIDS. But as the country rolls out new HIV prevention methods, questions remain: Are these interventions reaching those who need them most?
Monica Chinyama spoke to civil society leaders, the National AIDS Commission, and people living with HIV to assess whether Malawi is truly on track.
George Jobe, Executive Director of the Malawi Health Equity Network (MEHN), says progress has been made, but gaps remain in how HIV prevention strategies are being implemented.
“I believe that the current processes are still not sufficiently inclusive,” Jobe said.
He stressed that civil society organizations are crucial to ensuring HIV services reach marginalized and vulnerable populations. “Without meaningful community engagement, we risk designing interventions that do not respond to the real needs of the people,” he said.
Jobe also highlighted the need for transparency and accountability mechanisms to ensure that resources for HIV prevention and treatment are used effectively.
The National AIDS Commission (NAC) says it is enhancing prevention efforts through updated strategies and communication approaches.
Dr. Beatrice Matanje, Chief Executive Officer of NAC, explained that the commission, together with the Ministry of Health and development partners, is rolling out new messaging and communication materials to guide demand creation and social behavior change.
“The Long-Acting Injectable Cabotegravir (LEN) is among the newer prevention methods being introduced to reduce new HIV infections, particularly among high-risk populations,” Dr. Matanje said. “Our focus is on increasing awareness and demand so that eligible individuals can access these services.”
Lenacapavir, a long-acting injection that can protect someone from HIV for several months. Because it does not require a daily pill, it may help people who find it difficult to take medicine every day.
Other forms of PrEP include daily pills such as Truvada and long-acting injections like Cabotegravir. These medicines work by stopping the HIV virus from establishing infection in the body.
By providing different options, PrEP helps more people protect themselves from HIV, which can help reduce new infections in Malawi and support global goals set by UNAIDS to end HIV as a public health threat by 2030.
One respondent noted that stigma remains a significant barrier. “People are still afraid to disclose their status because of how society treats them,” they said.
Another highlighted the importance of consistent drug supply and respectful treatment at health facilities. “Sometimes services are there, but how people are treated at the facility matters. We need more support at community level,” they added.
These experiences mirror civil society concerns that medical interventions alone are insufficient without addressing social barriers.
Efforts to obtain a response from the Ministry of Health were unsuccessful by the time of publication. Officials had not provided information on how the government is measuring the impact of newly introduced prevention methods or how funding challenges may affect implementation.
While Malawi has made notable progress in the fight against HIV, the introduction of new prevention methods alone may not guarantee the country reaches its 2030 target.
As the 2030 deadline approaches, Malawi’s success will depend not only on new technologies but on whether policies are inclusive, communities are empowered, and accountability mechanisms are strengthened.
The fight against HIV is not just a medical battle it is a test of leadership, equity, and collective responsibility.
